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Abstract
Background: The highly resistant nature of glioblastoma multiforme (GBM) to chemotherapy prompted us to
evaluate the efficacy of bicyclic triterpenoid Iripallidal against GBM in vitro.
Methods: The effect of Iripallidal on proliferation and apoptosis in glioma cell lines was evaluated by MTS, colony
formation and caspase-3 activity. The effect of iripallidal to regulate (i) Akt/mTOR and STAT3 signaling (ii) molecules
associated with cell cycle and DNA damage was evaluated by Western blot analysis. The effect of Iripallidal on
telomerase activity was also determined.
Results: Iripallidal (i) induced apoptosis, (ii) inhibited Akt/mTOR and STAT3 signaling, (iii) altered molecules
associated with cell cycle and DNA damage, (iv) inhibited telomerase activity and colony forming efficiency of
glioma cells. In addition, Iripallidal displayed anti-proliferative activity against non-glioma cancer cell lines of diverse
origin.
Conclusion: The ability of Iripallidal to serve as a dual-inhibitor of Akt/mTOR and STAT3 signaling warrants further
investigation into its role as a therapeutic strategy against GBM.
Introduction
Iripallidal [(-) (6R,10S,11S,18R,22S)-26-Hydroxy-22-
a-methylcycloirid-16-enal NSC 631939]- a bicyclic
triterpenoid isolated from Iris pallida belongs to the ter-
penoid family as Paclitaxel. Paclitaxel is an effective che-
motherapy for several types of neoplasms [1]. Iripallidal
inhibited cell growth in a NCI 60 cell line screen [2]
and induced cytotoxicity in human tumor cell lines [3].
Besides the fact that Iridals are ligands for phorbol ester
receptors with modest selectivity for RasGRP3 [2], not
much is known regarding its mechanism of action.
Despite recent advances in understanding molecular
mechanisms involved in GBM progression, the prognosis
of the most malignant brain tumor continues to be dis-
mal. Ras activation occurs in GBMs [4] and this high
level of active Ras has been a target for glioma therapy.
RasGRP3- is an exchange factor that catalyzes the forma-
tion of the active GTP-bound form of Ras-like small
GTPases [5]. Importantly, Ras activation stimulates its
downstream effector Akt that plays a major role in glio-
blastoma development as ~80% of GBM cases express
high Akt levels [6]. Akt activates mammalian target of
rapamycin (mTOR), which is deregulated in glioblastoma
[7]. mTOR phosphorylates p70 ribosomal S6 kinase
(p70S6 kinase) that regulates translation of proteins
involved in cellular proliferation and formation. More-
over, blocking mTOR signaling reduces glioma cell pro-
liferation [8]. Given the importance of Akt/mTOR
signaling in glioma cell survival, significant efforts are
being invested in identifying inhibitors that target this
pathway [8-10]. In addition to aberrant PI3K/Akt signal-
ing; heightened STAT3 activation plays a critical role in
glioblastoma and STAT3 inhibitors have shown promise
as therapeutics for GBM [11-13]. In addition to RasGRP3
Iripallidal also binds to PKCa [2] which is known to
induce cells ectopically expressing hyperactive Ras to
undergo apoptosis [14]. Not only is STAT3 essential for
Ras transformation [15] but constitutively activated
STAT3 is negatively regulated by PKC-activated tyrosine
phosphatase(s) [16]. As Iridals interacts with PKCa and
RasGRP3-molecules that regulate Akt and STAT3 signal-
ing, and since inhibition of Akt/mTOR and STAT3 sig-
naling are being targeted for GBM treatment we
evaluated the effect of Iripallidal on glioma cell prolifera-
tion and these signaling pathways.* Correspondence: ellora@nbrc.ac.inNational Brain Research Centre, Manesar, Haryana 122 050, India
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Materials and methods
Cell culture and treatment
Glioblastoma cell lines A172, LN229, T98G and U87MG
were obtained from American Type Culture Collection
and cultured in DMEM supplemented with 10% fetal
bovine serum. Peripheral blood mononuclear cells
(PBMC) were isolated by Ficoll/Histopaque density gra-
dient centrifugation. Adherent monocytes were purified
from PBMC following adherence on glass petri-dish for
three hours after flushing the non-adherent cells by
extensive washing with PBS. All experiments with
human PBMC were conducted under an approved insti-
tutional Human Ethics Committee protocol.
On attaining semi-confluence, cells were switched to
serum free media and after 6 hours, cells were treated
with different concentration of Iripallidal (in Dimethyl
sulphoxide, DMSO) in serum free media for 24 hours.
DMSO treated cells were used as controls. Iripallidal was
purchased from Calbiochem, USA. All reagents were
purchased from Sigma unless otherwise stated. Colon
cancer cell line HT29, breast cancer line MCF-7, cervical
cancer cell line HeLa, hepatocellular carcinoma cell line
HepG2, acute myeloid leukemic cell line THP1 and
human monocytes were similarly treated with Iripallidal.
Determination of cell viability
Viability of Iripallidal treated monocytes and cancer cell
lines was assessed using the [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)- 2H-
tetrazolium, inner salt] (MTS) (Promega) as described
earlier [17].
Assay of Caspase 3 activity
The Colorimetric Assay kits for caspase 3 (Sigma) were
used to determine its enzymatic activity in Iripallidal
treated glioma cells as described previously [18].
Western Blot Analysis
Protein from whole cell lysates were isolated as described
previously [19]. Protein (20-50 μg) isolated from control
and Iripallidal treated cells was electrophoresed on 6% to
10% polyacrylamide gel and Western blotting performed
as described [19]. Antibodies were purchased from Cell
Signaling Technology (Danvers, MA) unless otherwise
mentioned. The following antibodies were used: p21 (BD
Biosciences), p27 (Abcam), pSTAT3 (Tyr705), pmTOR
(Ser2448), mTOR, Akt, pAkt (Ser473), Cyclin D1
(Abcam), phospho-p70S6K (Thr389), cMyc (Santa Cruz),
phospho-S6K (Ser235/236), pH2AX Ser139 (Upstate),
cleaved-PARP and b actin. Secondary antibodies were
purchased from Vector Laboratories. After addition of
chemiluminescence reagent (Amersham), blots were
exposed to Chemigenius, Bioimaging System (Syngene,
UK) for developing and images were captured using Gen-
esnap software (Syngene). The blots were stripped and
reprobed with anti-b-actin to determine equivalent load-
ing as described [19].
TeloTAGGG Telomerase PCR ELISA PLUS
Telomerase activity was determined using the Telo-
TAGGG Telomerase PCR ELISA PLUS kit (Roche,
Germany) as described previously [18].
Colony formation in soft agar
The soft agar colony formation assay was performed
using CytoSelect™ 96-Well Cell Transformation Assay
kit (Cell Biolabs, Inc), as described previously [20].
Statistical Analysis
All comparisons between groups were performed using
two-tailed Paired student’s t-Test. All values of p less
than 0.05 were taken as significant.
Results
Iripallidal decreases viability and induces apoptosis in
glioma cells
To determine whether Iripallidal affects viability of
glioma cells, MTS assay was performed on A172,
LN229, T98G and U87MG glioma cells treated with dif-
ferent concentrations of Iripallidal for 24 hours. While
no significant cell death was observed in cells treated
with 10 μM Iripallidal, a ~50% decrease in cell viability
was observed in all the glioma cell lines tested upon
treatment with 20 μM Iripallidal (Fig. 1a). Since the acti-
vation of caspase-3-like proteases is crucial in apoptotic
cell death [21], we determined the caspase-3 activity in
Iripallidal treated glioma cells. Decrease in viability was
accompanied by a significant ~2.5 to 3-fold increase in
caspase-3 activity in all the cell lines, as compared to
control (Fig. 1b). As Caspase-3 activity was elevated in
Iripallidal treated cells, we determined the expression of
PARP in these cells. Treatment with Iripallidal elevated
the level of cleaved PARP as compared to control, in all
glioma cells tested (Fig. 1c). Increase in caspase-3 activa-
tion and cleaved-PARP level was indicative of apoptosis
induction by Iripallidal. These results suggest that Iripal-
lidal induce apoptosis in glioma cells.
Iripallidal inhibits Akt/mTOR signaling in
glioblastoma cells
As aberrant activation of the PI3K/Akt occurs frequently
in glioblastomas [22], therapeutics approaches are direc-
ted towards targeting this pathway. Treatment with Iri-
pallidal decreased Akt phosphorylation in glioma cells
(Fig. 2). As inhibition of PI3 kinase p110a blocks Akt
phosphorylation in glioma cells [23], we investigated
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Figure 1 Iripallidal decreases viability and induces apoptosis of glioma cells. (a) Viability of Iripallidal treated glioma cells was determined
by MTS assay. The graph represents the percentage viable cells of control observed when A172, LN229, T98G and U87MG cells were treated
with 10 and 20μM concentration of Iripallidal for 24 hours. * Significant decrease from control (P < 0.05). (b) Increase in caspase-3 activity in
Iripallidal treated A172, LN229, T98G and U87MG cells as determined by the Caspase-3 activity. * Significant increase from control (P < 0.05).
(c) Treatment with Iripallidal increases cleaved PARP expression in glioma cells. Western blot analysis was performed to determine the expression
of cleaved and native PARP in Iripallidal treated glioma cells. A representative blot is shown from three independent experiments with identical
results. Blots were reprobed for b actin to establish equivalent loading. C and I denote Control and Iripallidal, respectively.
Figure 2 Iripallidal inhibits Akt/mTOR signaling in glioma cells. Western blot analysis was performed to determine the status of Akt/mTOR
pathway in A172, LN229, T98G and U87MG glioma cells treated with 20 μM of Iripallidal for 24 hrs. A decrease in pAkt, pmTOR, pP70S6 kinase
and pS6 kinase levels was observed upon Iripallidal treatment. Representative blot is shown from three independent experiments with identical
results. C and I denote control and Iripallidal, respectively. Blots were reprobed for b-actin to establish equivalent loading.
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whether this decrease in pAkt was the consequence of
reduced p110a levels. Iripallidal had no effect on p110a
levels (Fig. 2). As Iripallidal inhibited pAkt, we investi-
gated its effect on Akt downstream target mTOR. Iripal-
lidal downregulated phospho-mTOR in glioma cells
(Fig. 2).
mTOR activation results in phosphorylation of effector
molecule p70S6K and S6 ribosomal protein, which sub-
sequently leads to mTOR-dependent gene transcription
that regulates cell growth, protein synthesis, and meta-
bolism. We therefore determined the effect of Iripallidal
on the status of p70S6K and pS6 kinase. Iripallidal
inhibited phosphorylation of mTOR targets 70S6K and
ribosomal protein S6 (Fig. 2). These results indicate that
iripallidal acts as a dual inhibitor of Akt/mTOR
pathway.
Iripallidal downregulates STAT3 phosphorylation in
glioma cells
As mTOR inhibitor blocks STAT activation and glial
differentiation [24] and since STAT3 inhibitors induce
apoptosis in glioma cells [12], we determined the status
of STAT3 activation in Iripallidal treated cells. A
decrease in pSTAT3 Tyr705 was observed upon Iripalli-
dal treatment (Fig. 3). These results indicate that Iripalli-
dal inhibits STAT3 activation in glioma cells.
Iripallidal affects expression of molecules involved in cell
cycle regulation and DNA damage response
Inhibition of PI3-K/Akt/mTOR signaling effects cell
cycle progression [23,25]. mTOR inhibitors induce cell
cycle arrest through down regulation of Cyclin D and
upregulation of p27 [8]. Since Iripallidal inhibited glioma
cell proliferation, we determined the expression of mole-
cules associated with cell cycle progression. An increase
in p21 and p27, and decrease in cyclin D1 and cMyc
levels was observed in glioma cells upon Iripallidal treat-
ment (Fig. 4a).
As maintained DNA breaks induce apoptosis [26] and
since H2AX is phosphorylated at sites of DNA double-
strand breaks [27], we determined the expression of
g-H2AX in Iripallidal treated cells. While an increased
g-H2AX expression was observed in Iripallidal treated
cells (Fig. 4b), the levels of total H2AX was unaffected
(Fig. 4b).
Iripallidal suppresses telomerase activity in glioma cells
Inhibition of telomerase activity is an important antic-
ancer modality since its inhibition causes apoptosis in
human cancers [28]. Telomerase activity is regulated
by Ras/PI3K/Akt pathway [29] and mTOR inhibitor
rapamycin inhibits telomerase activity in endometrial
cancer cells [30]. Besides, STAT3 regulates human tel-
omerase reverse transcriptase (hTERT) expression in
human cancer and primary cells [31]. Also, we have
shown that inhibition of telomerase activity is asso-
ciated with decrease glioma cell proliferation [18,20].
Since Iripallidal inhibits mTOR and STAT3 activation
in glioma cells we investigated its ability to regulate
telomerase activity. An approximate 50% reduction in
telomerase activity was observed in glioma cells upon
treatment with 20 μM Iripallidal (Fig. 5a). Telomerase
inhibitors are known to reduce colony formation in
soft agar assays [32] and STAT3 is essential for ancho-
rage-independent growth of transformed cells [33].
Since Iripallidal decreased glioma cell survival we
determined the ability of Iripallidal to effect the ancho-
rage independent growth of glioma cells. Treatment
with 20 μM Iripallidal reduced colony forming ability
of glioma cells in soft agar by ~40%, as compared to
control (Fig. 5b).
Iripallidal inhibits proliferation of non-glioma cancer cells
of diverse origin in vitro
We next evaluated whether Iripallidal also exhibits anti-
proliferative property against other human malignancies,
by testing its effects against a panel of non-glioma
human cancer cell lines in vitro. Treatment with 20 μM
Iripallidal reduced viability of MCF-7, HeLa, HepG2,
THP1 and HT-29 cells lines by ~35% to 60%, as
Figure 3 Treatment with Iripallidal decreases STAT3 phosphorylation in glioma cells. Western blotting analysis demonstrates a decrease in
pSTAT3 levels in A172, LN229, T98G and U87MG glioma cells upon Iripallidal treatment. Representative blot is shown from three independent
experiments with identical results. C and I denote control and Iripallidal, respectively. Blots were reprobed for b-actin to establish equivalent
loading.
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compared to their respective controls (Fig. 6a). These
findings indicate that Iripallidal not only inhibits prolif-
eration of GBM, but also exhibits anti-proliferative
activity against a wide variety of human cancers. To
show the selectivity of Iripallidal for tumor cells, the
effect of Iripallidal was investigated on normal human
monocytes. Treatment of monocytes with Iripallidal
induced ~8-10% decrease in viability, suggesting that the
anti-proliferative ability of Iripallidal is selective for
transformed cells (Fig. 6b).
Figure 4 Iripallidal effects expression of cell cycle regulators and DNA damage repair response molecules. Representative blot is shown
from three independent experiments with identical results. C and I denote control and Iripallidal, respectively. Western blot analysis reveals (a)
increase in p21, p27 and decrease in cyclin D1, cMyc levels (b) increase in gH2AX in A172, LN229, T98G and U87MG glioma cells treated with
20 μM Iripallidal, as compared to control. Figures (a) and (b) are representative blot shown from three independent experiments with identical
results. Blots were reprobed for b-actin to establish equivalent loading.
Figure 5 Iripallidal decreases hTERT activity and colony forming ability of glioma cells. (a) Glioma cells were treated with 20 μM Iripallidal
and TeloTAGGG Telomerase PCR ELISA was performed. A decrease in hTERT activity was observed in Iripallidal treated cells as compared to control.
(b) Iripallidal decreases the ability of glioma cells to form colonies in soft agar. Soft agar assay was performed on cells that were left untreated or
treated with Iripallidal for 6 days. The graph indicates the percentage of colonies formed. Values in (a) and (b) represent the means ± SEM from 3
individual experiments. * Significant decrease from control (P < 0.05).
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Discussion
In vitro screening of compounds with anticancer proper-
ties by NCI identified Iridals for their anti-proliferative
activity. Besides its ability to bind PKCa and RasGRP3 [2],
nothing is known regarding the mechanism of action or
bioavailability of Iripallidal. Our studies suggest that Iripal-
lidal induce apoptosis in glioma cells and inhibits the Akt/
mTOR pathway. The efficacy of mTOR inhibitors in glio-
blastoma cell lines [8,10] has prompted their clinical trials
for GBM [9,34]. As rapamycin activates Akt pathway by a
negative feedback loop involving phosphorylation of insu-
lin receptor substrate (IRS) by mTOR effector molecule S6
kinase [35,36], it was therefore not surprising that Rapa-
mycin treatment induced Akt activation in some GBM
patients in a Phase I clinical trial [9]. Moreover, dual inhi-
bition of Akt and mTOR has proven effective in pre-clini-
cal model of GBM [23], suggesting that dual Akt/mTOR
inhibitor can effectively overcome the effects of feeback
loop efficiently than a single inhibitor selectively targeting
mTOR. As mTOR blockade is a biomarker of therapeutic
efficacy in glioma [37], the unique ability of Iripallidal to
inhibit both Akt and mTOR can be exploited as novel
anti-glioma therapy. In addition to inhibiting Akt/mTOR
axis, Iripallidal also inhibited STAT3 signaling. PKC inhi-
bitor attenuates Ras activation and this attenuation corre-
lates with an inhibition of RasGRP3 phosphorylation [38].
Interestingly, PKCa regulates mTOR [37] as well as
STAT3 activation [16]. It is possible that Iripallidal effects
Akt/mTOR and STAT3 signaling pathways through its
ability to bind PKC.
Iripallidal mediated decrease in STAT3 activation was
concurrent with decreased cyclin D1 and increased p21
expression. While cyclin D1 overexpression and STAT3
activation are mutually exclusive events [39], p21 inhibits
STAT3 signaling [40]. Besides, inhibition of mTOR signal-
ing induces cell cycle arrest through regulation of Cyclin
D and p27 [8]. As telomerase inhibition is known to cause
apoptosis in human cancers [28], the ability of Iripallidal
to down-regulate telomerase activity may also represent a
mechanism for its anti-proliferative effect on glioma cells.
Besides glioma cell lines, Iripallidal also decreased the via-
bility of several other cancer cell types although to differ-
ent extents. It is known that cytotoxic responses is a
reflection of an integrated readout of all targets and/or
biochemical pathways affected upon drug exposure [41].
As strong co-relation exists between chemo-responsive-
ness and gene expression [41], it is likely that differential
expression of cellular pathways in cancer cell types of
diverse origin could have resulted in differences in sensi-
tivity to Iripallidal.
Taken together our studies suggest that (i) Iripallidal
induces glioma cell apoptosis and (ii) inhibits Akt/mTOR
and STAT3 pathway. This ability of Iripallidal to act as a
multi-inhibitor that blocks Akt/mTOR and STAT3 path-
ways suggest that its potential as a chemotherapeutic
agent against GBM should be further evaluated. Impor-
tantly, Iripallidal is not only a promising candidate for
the treatment of GBM but a wide variety of malignancies,
since it elicits cell death in many tumor cell types.
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